VIVELLE by Novartis is characteristics. First approved in 2000.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
VIVELLE is a transdermal estradiol patch approved in 2000 for hormone replacement therapy and related indications. It delivers estradiol via an extended-release film formulation applied to the skin. The drug works by replacing or supplementing endogenous estrogen in patients with estrogen deficiency.
With LOE approaching and moderate competitive pressure (30), the VIVELLE team is likely stabilizing operations and preparing for market transition; smaller team focus expected.
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VIVELLE offers exposure to mature product lifecycle management in a legacy but stable market. Career value lies in managing LOE transition, generic competition strategies, and optimizing commercial execution in a declining-growth environment.
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.